PPARG and Insulin resistance: Although the therapeutic potential of PPARβ/δ for metabolic diseases such as insulin resistance, dyslipidemia, and other associated liver pathologies deserves further investigations, agonists of PPARγ and PPARα have been developed as relevant drugs to treat these disorders.